Toll-like receptor-4 signaling in mantle cell lymphoma: Effects on tumor growth and immune evasion

Cancer

Volumn 119, Issue 4, 2013, Pages 782-791

  Wang, Lijuan ^a,b   Zhao, Yi ^b   Qian, Jianfei ^a   Sun, Luhong ^a   Lu, Yong ^a   Li, Haiyan ^a   Li, Yi ^b   Yang, Jing ^a   Cai, Zhen ^b   Yi, Qing ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

cytotoxic T lymphocytes; immune evasion; lipopolysaccharide; mantle cell lymphoma; Toll like receptor 4

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; VASCULOTROPIN;

ARTICLE; CANCER PATIENT; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LYMPHOMA CELL; LYMPHOMA CELL LINE; MANTLE CELL LYMPHOMA; PRIMARY TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; TUMOR GROWTH;

CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IMMUNE EVASION; INTERLEUKIN-10; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LYMPHOMA, MANTLE-CELL; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84873413850     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27792     Document Type: Article

References (31)

1. Perez-Galan P, Dreyling M, Wiestner A,. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011; 117: 26-38.
2. Dreyling M, Hiddemann W,. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program. 2009; 2009: 542-551.
3. Ghielmini M, Zucca E,. How I treat mantle cell lymphoma. Blood. 2009; 114: 1469-1476.
4. Leonard JP, Williams ME, Goy A, et al. Mantle cell lymphoma: biological insights and treatment advances. Clin Lymphoma Myeloma. 2009; 9: 267-277.
5. Rook GA, Dalgleish A,. Infection, immunoregulation, and cancer. Immunol Rev. 2011; 240: 141-159.
6. Li X, Jiang S, Tapping RI,. Toll-like receptor signaling in cell proliferation and survival. Cytokine. 2010; 49: 1-9.
7. Akira S, Takeda K,. Toll-like receptor signalling. Nat Rev Immunol. 2004; 4: 499-511.
8. Schmidt C,. Immune system's Toll-like receptors have good opportunity for cancer treatment. J Natl Cancer Inst. 2006; 98: 574-575.
9. Wolska A, Lech-Maranda E, Robak T,. Toll-like receptors and their role in hematologic malignancies. Curr Mol Med. 2009; 9: 324-335.
10. Zhao WJ, Xi LY, Ma L,. [Effect of Penicillium marneffei on TLR-2, TLR-4, and Dectin-1 expression and TNF-alpha production in macrophage.] Nan Fang Yi Ke Da Xue Xue Bao. 28: 37-40, 2008.
11. Tichomirowa M, Theodoropoulou M, Lohrer P, et al. Bacterial endotoxin (lipopolysaccharide) stimulates interleukin-6 production and inhibits growth of pituitary tumour cells expressing the toll-like receptor 4. J Neuroendocrinol. 2005; 17: 152-160.
12. Chicoine MR, Zahner M, Won EK, et al. The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4. Neurosurgery 60: 372-380, 2007; discussion 381.
13. Andreani V, Gatti G, Simonella L, Rivero V, Maccioni M,. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res. 2007; 67: 10519-10527.
14. Pinto A, Morello S, Sorrentino R,. Lung cancer and Toll-like receptors. Cancer Immunol Immunother. 2011; 60: 1211-1220.
15. Szajnik M, Szczepanski MJ, Czystowska M, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 2009; 28: 4353-4363.
16. Bao H, Lu P, Li Y, et al. Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack. Cancer Biol Ther. 2011; 11: 58-67.
17. Xu Y, Zhao Y, Huang H, et al. Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB. Br J Haematol. 2010; 150: 543-553.
18. Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D,. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res. 2011; 71: 2466-2475.
19. Song EJ, Kang MJ, Kim YS, et al. Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. Int J Mol Med. 2011; 28: 115-119.
20. Qian J, Xie J, Hong S, et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007; 110: 1587-1594.
21. Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q,. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood. 2006; 107: 2432-2439.
22. Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ,. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem. 2011; 18: 2257-2262.
23. Sahoo M, Ceballos-Olvera I, del Barrio L, Re F,. Role of the inflammasome, IL-1beta, and IL-18 in bacterial infections. ScientificWorldJournal. 2011; 11: 2037-2050.
24. Wolska A, Lech-Maranda E, Robak T,. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett. 2009; 14: 248-272.
25. Rakoff-Nahoum S, Medzhitov R,. Toll-like receptors and cancer. Nat Rev Cancer. 2009; 9: 57-63.
26. He W, Liu Q, Wang L, Chen W, Li N, Cao X,. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007; 44: 2850-2859.
27. Nunez NG, Andreani V, Crespo MI, et al. IFNbeta produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. Cancer Res. 2012; 72: 592-603.
28. Toshchakov VY, Szmacinski H, Couture LA, Lakowicz JR, Vogel SN,. Targeting TLR4 signaling by TLR4 Toll/IL-1 receptor domain-derived decoy peptides: identification of the TLR4 Toll/IL-1 receptor domain dimerization interface. J Immunol. 2011; 186: 4819-4827.
29. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol. 2010; 11: 141-147.
30. Lysakova-Devine T, Keogh B, Harrington B, et al. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule. J Immunol. 2010; 185: 4261-4271.
31. Tang B, Xiao B, Liu Z, et al. Identification of MyD88 as a novel target of miR-155, involved in negative regulation of Helicobacter pylori-induced inflammation. FEBS Lett. 2010; 584: 1481-1486.